Skip to main content
. Author manuscript; available in PMC: 2024 Jul 1.
Published in final edited form as: Ann Oncol. 2023 Apr 25;34(7):615–625. doi: 10.1016/j.annonc.2023.04.006

Figure 5. KIT/PDGFRA primary and secondary mutations determined in ctDNA in GIST are prognostic of TKI activity.

Figure 5.

(A) KIT secondary mutations did not significantly affect the number of partial responses between treatments arms. Avapritinib efficacy was similar between primary KIT exon 9 and 11 mutations (B), whereas regorafenib trended to be more effective in patients with a primary exon 11 mutation (C). (D) Avapritinib had greater efficacy in patients with a primary PDGFRA exon 18 D842V mutation than regorafenib. CI, confidence interval; mPFS, median progression-free survival; NE, not estimable; PD, progressive disease; PR, partial response; SD, stable disease.